Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment OutlookSeeking Alpha • 10/24/25
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?Zacks Investment Research • 10/20/25
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/09/25
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 10/08/25
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should KnowZacks Investment Research • 10/08/25
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 10/08/25
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathyGlobeNewsWire • 09/25/25
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy ThesisSeeking Alpha • 09/19/25
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock UpZacks Investment Research • 09/19/25
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?Zacks Investment Research • 09/19/25
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary AngioedemaGlobeNewsWire • 09/18/25
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%The Motley Fool • 09/11/25
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in FocusZacks Investment Research • 08/08/25
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/07/25
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/01/25
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 07/31/25
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company UpdatesGlobeNewsWire • 07/31/25